<DOC>
	<DOCNO>NCT00523393</DOCNO>
	<brief_summary>In trial , study whether early addition long act insulin analogue Glargine capable increase number differentiation endothelial progenitor cell ( EPC ) patient type 2 diabetes , see marker vascular regenerative potential cardiovascular risk . In addition , effect Glargine microvascular function study . This do use laser Doppler measurement skin ; addition , MRI heart perform capable quantify perfusion reserve myocardium additional functional aspect ventricular function . A beneficial effect early addition bedtime Glargine EPC vascular well myocardial function study might argue change therapeutic approach type 2 diabetes possibly improve cardiovascular outcome patient affect .</brief_summary>
	<brief_title>Prospective Influence Bedtime Insulin Glargine Mobilization Function Endothelial Progenitor Cells</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Oral antidiabetic therapy Age 35 70 6,5 % &lt; HbA1c ≤ 9 % Ability subject understand character individual consequence clinical trial Written inform consent must available enrollment trial For woman childbearing potential , adequate contraception ( Pearl Index &lt; 1 % , e.g . birth control pill ) negative blood pregnancy test 6,5 % &lt; HbA1c ≤ 9 % Ability subject understand character individual consequence clinical trial Written inform consent must available enrollment trial For woman childbearing potential , adequate contraception ( Pearl Index &lt; 1 % , e.g . birth control pill ) negative blood pregnancy test MODY Malignant disease Hematopoietic disorder Impairment renal function ( Serum creatinine &gt; 1,5mg/dl ) autoimmune disease treatment immunosuppressive drug Psychiatric disease Myocardial ischemia previous 6 month Acute coronary syndrome pAVK IIb , III , IV ( FontaineRatschow ) Erythropoietin treatment Glitazone treatment two week inclusion Insulin treatment two week inclusion Pregnancy lactation History hypersensitivity investigational product drug similar chemical structure excipient present pharmaceutical form investigational product Participation clinical trial observation period compete trial , respectively No subject allow enroll trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>